Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catiolanze vs Xalatan in Glaucoma/OHT
NCT04133311Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Catiolanze in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Intraocular Pressure Change at Week 12 (09:00) and Intraocular Pressure Change at Week 12 (16:00). Started Apr 2019; status: completed.
02
Drugs
Catiolanze
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04133311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133311.